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Abstract
We describe two female monozygotic 
(MZ) twins heterozygous for Fabry dis­
ease, an X linked disorder resulting from 
the deficient activity of a-galactosidase A. 
While one of the twins was clinically 
affected, the other was asymptomatic. 
Enzymatic assay of a-galactosidase in 
blood leucocytes, skin fibroblasts, 
Epstein-Barr virus transformed lym­
phoid cell lines, and hair follicles of the 
twins and their parents confirmed the 
heterozygous status of the twins and indi­
cated that Fabry disease had occurred as a 
result of a de novo mutation. The son of 
the unaffected twin sister was shown to be 
hemizygous. Molecular analysis of the 
a-galactosidase A gene permitted the 
identification of an as yet undescribed 
point mutation at position 10182 of exon 5 
which causes an Asp to Asn substitution at 
codon 231. Single strand conformation 
polymorphism (S S CP) analysis again 
showed the heterozygous status of the 
twins and a normal pattern in their 
parents. The basis for the discordant 
expression of this de novo mutation in the 
twins was investigated by studying their X 
inactivation status. Analysis of the inac­
tive X specific methylation at the andro­
gen receptor gene showed unbalanced 
inactivation in the twins’ fibroblasts and 
in opposite directions. While the mater­
nally derived X chromosome was prefer­
entially active in the asymptomatic twin, 
the paternal X chromosome was active in 
the other, affected twin and was found in 
her hemizygotic nephew. These data sug­
gest that the paternal X chromosome car­
ries the de novo a-galactosidase A muta­
tion and that uneven X inactivation is the 
underlying mechanism for disease expres­
sion in this novel female MZ twin pair. 
This is the first documented case of female 
twins discordant for Fabry disease.
(3Med Genet 1996;33:682-688)
Key words: Fabry disease; X inactivation; monozygotic 
twins.
In female mammals,, compensation for sex dif­
ferences in the dosage of most X chromosomal 
genes occurs during early embryogenesis
through X  inactivation,1"3 This phenomenon 
results in selective, irreversible inactivation of 
either the maternal or the paternal X chromo­
some of each somatic cell. Since X inactivation 
occurs at random and is maintained in all 
daughter cells, females exhibit a mosaic pattern 
of expression of X  linked genes, each X  
chromosome being active in about half of all 
somatic cells. However, if one X  chromosome 
is predominantly inactivated in a female 
heterozygous for an X linked trait, this may 
lead to severe manifestation of the X  linked 
disorder.
Such a situation can be observed in female 
monozygotic (MZ) twins who are hetero­
zygous for an X  linked disorder. In all the pairs 
(22) of heterozygous identical female twins 
published so far,4“7 there was discordant 
expression of the disease, that is, only one twin 
was clinically affected, which is interpreted as 
the consequence of skewed X inactivation in 
opposite directions in each of the MZ twins. 
Since expression of an X  linked disorder in 
both female twins has never been described, an 
interrelation between twinning and X inactiva­
tion has been postulated.8-11
In this study, we report the occurrence of 
female MZ twins with discordant expression of 
Fabry disease. Anderson-Fabry disease (MIM  
301500) is an X  linked disorder caused by the 
deficient activity of the lysosomal exoglycohy­
drolase, a-galactosidase A (EC 3 .2 .1 .22).12 
The gene encoding a-galactosidase A, which 
contains seven exons and extends over 12 kb, is 
localised on the long arm of the X chromo­
some (Xq22) .13 14 In addition, the 
a-galactosidase A gene has previously been 
shown to be affected by X  inactivation.15 Loss 
of this enzyme activity results in the progressive 
lysosomal storage of glycosphingolipids with 
terminal a-galactose residues. Affected 
hemizygous males accumulate mainly globo- 
triosylceramide and galabiosylceramide within 
the vascular endothelium. Clinical manifesta­
tions include angiokeratoma, pain in the 
extremities, corneal opacities, renal failure, and 
vascular disease of the heart and brain. Most 
heterozygous females are clinically asympto­
matic or have minimal symptoms (the most 
frequent being characteristic keratopathy), 
although some heterozygotes have been re­
ported to be as severely affected as hemizygous 
males.12 While Fabry disease in males can be 
definitively diagnosed by demonstration of
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Table 1 Short tandem repeat (STR) analysis of the twin sisters
STR  locus
Chromosome
location
Patient
1.1 1.2 112 II. 3
HPRT Xq26 283 287;287 283;287 283;287
FABP2 4q28-q31 206;206 215;218 206;215 206;215
CSF1R 5q33-q34 308;308 308;312 308;308 308;308
T H llp l5 .5 183;193 199;199 193;199 193;199
PLA2A 12q23-qter 121;127 119; 121 121;127 121 ;127
F13A1 6p24-p25 281;293 290;290 290;293 290;293
CYP19 15q21.1 175;175 175;175 175;175 175;175
LPL 8p22 124; 124 120;128 124;128 124;128
FES 15q25-qter 143;151 147; 155 147;151 147;151
VWF 12pl3 166;170 154;162 162;166 162;166
Allele identification was achieved as described in the M ethods section. For each m em ber of the 
family, the length of the PCR products is given (in bp).
STR loci are named according to the Genome Database designation, as reported in reference 
24. The Genome Database designations of FES and VWF are GOO-156-258 and GOO-155-481» 
respectively.
deficient a-galactosidase A activity, enzymatic 
identification o f female carriers is often incon­
clusive because of the very wide range o f  
a-galactosidase A activity levels owing to the 
random X  chromosomal inactivation phenom ­
enon.
We report here for the first time the 
enzymatic and molecular identification, as well 
as the characterisation of the X  inactivation 
status, of female MZ twins discordant for 
Fabry disease.
Family history
The clinical and pathological features of this 
Fabry disease family have been described in 
detail elsewere,lû Briefly, a 26 year old woman 
(patient II. 2, fig 1) was investigated on the 
basis o f angiokeratomas, with the characteristic 
"swimsuit” distribution. The history indicated 
the onset of symptoms at the age of 16 years, 
with a progressive course including acroparaes- 
thesia in all four limbs. Further evaluation of 
the patient showed isolated proteinuria and the 
presence of a verticillate cornea and vascular 
tortuosities on optic fundus examination. Elec­
tron microscopy of the skin and renal biopsies 
showed the typical p attern of concentric, 
lamellar inclusions and thin layer chromato­
graphic analysis of the urine showed large 
amounts of tri- and dihexosylceramide.
The twin sister (II.3) showed no skin lesions. 
No verticillate cornea was found and there was 
no history of acroparaesthesia. Only some 
vacuolated endothelial cells in a skin biopsy 
and trace amounts of trihexosylceramide were 
found.16 Monozygosity was strongly suspected  
on the basis of the physical similarities, finger 
prints, and identity of erythrocyte and HLA  
groups.16
Screening of the rest of the family indicated 
tliat the son of the unaffected twin (patient
III.2) was hemizygous.
1
II
Figure 1 Pedigree of the Fabry disease family. IL 2 
(arrow) is the twin manifesting Fabry disease.
M ethods
ISOLATION OF CELLS AND CELL CU LTU RE
Tissue samples were obtained from subjects 
with informed consent. Leucocytes from 
heparinised blood were isolated17 using Plas- 
magelR (Roger Bellon Lab, Paris, France). Skin 
fibroblasts were obtained from forearm skin 
biopsies. Lymphoid cell lines were established 
by Epstein-Barr virus transformation of blood 
B lymphocytes obtained from controls and 
from our patients. M ononuclear cells were iso­
lated from 10 ml heparinised blood on Ficoll- 
HistopaqueR (Sigma, LTsle d’Abeau Chesnes, 
France) gradient and, after washing, sus­
pended in RPMI 1640 medium containing 
Epstein-Barr virus B95-8 strain.IH After 24  
hours’ incubation, half of this medium was 
replaced by fresh medium supplemented with 
cyclosporin A and the culture was continued as 
previously described.18 Lymphoid cells and 
skin fibroblasts were grown in a humidified 5 % 
C 0 2 atmosphere at 37°C in RPMI 1640 
medium (Gibco BRL, Cergy-Pontoise, 
France) supplemented with L-glutamine (2 
mmol/1), penicillin (100 U /m l), streptomycin 
(100 jig/ml), and heat inactivated fetal calf 
serum ( 10%), as previously reported.19 Cells 
were harvested by slow speed centrifugation 
and washed three times with PBS. Cell pellets 
were kept frozen at -70°C until use.
ENZYME STUDIES
a-Galactosidase activity was assayed in ex­
tracts of peripheral blood leucocytes, cultured 
skin fibroblasts, and Epstein-Barr virus trans­
formed lymphoid cells in the presence of
4-methylumbelliferyl-a-D-galactopyranoside 
as previously described .19 a-Galactosidase A  
activity was specifically determined20 using 
heat stability assays or in the presence of a -N -  
acetylgalactosamine. a-Galactosidase activity 
was also measured on single hair roots as 
previously reported21 2Z; hair root activities 
were expressed as a ratio of a-galactosidase/p- 
hexosaminidase. The activity of 
[î-hexosaminidase was determined as de­
scribed previously.*6 19 22
D N A  ANALYSES
Preparation of genomic D N A
Fibroblast and lymphoid cell pellets were
suspended in 1 ml of lysis buffer (10 mmol/1
Tris-HCl, pH  8, 100 mmol/1 NaCl, 1 mmol/1 
EDTA, 1% SDS) with proteinase K  (200  
jtg/ml) and incubated overnight at 56°C. 
Genomic D N A  was extracted with phenol- 
chloroform (two cycles), precipitated with 
ethanol, and resuspended in deionised water 
for amplification by the polymerase chain reac­
tion (PCR).23
Polymorphism studies
T he twin sisters and their parents were tested 
for zygosity by short tandem repeats (STR) 
loci PCR analysis as previously 
reported24 (table 1) using die ALF Fragment 
Manager (Pharmacia).
a - Galactosidase A  D N A  amplification
T he seven exons encoding a-galactosidase A
and their flanking sequences were PCR ampli-
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Table 2 a-Galcictosidase activity in cells derived from members o f the affected family
Enzyme Cell type
Patient
L I 12 I I I I I  2 I I I I II. 3 I I I  2 Controls (mean (SD))
a-Gal Leucocytes 37 30.5 27 14 38 15 3.5 36 (6)
Fibroblasts 13 62 90 (20)
LCL 22.0 7.8 11.0 0.85 21.6 (6.4)
oc-Gal/ß-Hex Leucocytes 0.042 0.035 0.032 0.016 0.036 0.008 0.002 0.035 (0.01)
Fibroblasts 0.002 0.010 0.015 (0,005)
«-Galactosidase (a-Gal) and total (3-hexosaminidase (fi-Hex) activities were assayed as described in Methods, and are expressed 
as nmol of methylumbel life rone released per hour per mg of cell protein. LCL=lymphoid cell lines.
fied using previously described primers.25 The 
amplification was performed in 33 cycles, each 
cycle consisting of one minute denaturation at 
94°C, one minute annealing at 55°C, and two 
minutes extension at 72°C. The reaction 
mixture contained 400 ng of high molecular 
weight DNA, 400 ng of each primer, 200 
jimol/1 of each dNTP, 100 jiig/ml bovine serum 
albumin, 67 mmol/1 Tris-HCl (pH 8 .8), 6.7 
mmol/1 M gCl2, 10 mmol/1 P-mercaptoethanol,
6.7 nmol/1 EDTA, 16.6 mmol/1 (NH 4)2S 0 4, 
10% dimediylsulphoxide, and 40 U/ml of Taq 
DNA polymerase (Cetus Corp, Emeryville, 
CA, USA). The amplified fragments were ana­
lysed by electrophoresis on 2% agarose gels.
Nucleotide sequence determination 
The amplified D N A  was purified by ultralow 
gelling temperature gel electrophoresis. The 
excised fragments were directly sequenced by 
the dideoxy chain termination reaction with a 
pUC sequencing kit (Boehringer Mannheim, 
Mannheim, Germany), using [a-35S] dATP 
(600 Ci/mmol). The amplification primers 
were used as primers in the sequencing 
reaction.
Single strand conformation polymorphism
(SSCP)
SSCP was identified by automated electro­
phoresis on 12,5% homogeneous PhastGels 
(Pharmacia-LKB) with native buffer strips for 
200 Vh at 4°C according to the manufacturer’s 
instructions. The D N A  was visualised by silver 
staining.
Analysis of X  inactivation patterns 
The X inactivation pattern analysis was per­
formed by studying the methylation of the 
H hal sites in the first exon of the human 
androgen receptor locus as previously re­
ported,26 DNA samples (1 jug, 20 |_l1) were 
digested with 20 U  of H hal (Gibco BRL Life 
Technologies), or incubated in the same buffer 
without enzyme, for 10 hours at 37°C. Ten 
microlitre aliquots were amplified by PCR  
(100 jj.1 final volume) with 0.5 p.mol/1 of each 
primer (syndiesised by Eurogentec, Seraing, 
Belgium), 200 jamol/1 dNTPs, 2.5 U  Tag DNA  
polymerase (Eurobio, Les Ulis, France), 10 
mmol/1 Tris-HCl (pH 9), 50 mmol/1 KC1, 
0.1 % Triton X -100, and 2.5 mmol/1 MgCl2. 
Samples were amplified using a TRIO- 
Thermoblock (Biometra, Gottingen, Ger­
many) for 35 cycles, each consisting of a dena­
turing step at 95°C for one minute, an 
annealing step at 60°C for 30 seconds, and an 
extension step at 72°C for 30 seconds. Aliquots
of the PCR products were analysed on a 12% 
polyacrylamide (29:1) non-denaturing gel. 
Relative intensity of bands after ethidium bro­
mide staining was assessed by densitometry 
using a Biocom scan. The size of the amplified 
fragments averaged 280 bp, which corresponds 
to 11-31 CAG repeat units.26
Results
CYTOGENETIC AND POLYMORPHISM STUDIES
Cytogenetic analysis showed normal karyo­
types in both twins. The sisters shared the 
same alleles for all STR markers tested. Prod­
uct length of each marker is shown in table 1 
for botli parents and the sisters. The PLA2A, 
VWF, and FES markers were informative for 
both parents, the CYP19 marker was not 
informative, and the other six markers were 
informative for a single parent. From these 
data it can be calculated that die sisters II.2 
and II.3 are monozygotic twins with a prob­
ability of 99.98%.
a-GALACTOSIDASE ENZYME STUDIES
As illustrated in table 2, both the clinically 
affected woman (patient II.2) and her clinically 
unaffected MZ twin sister (patient II.3) exhib­
ited clearly reduced levels of a-galactosidase 
activity in various cell types, indicating their 
heterozygous status for the Fabry trait. The 
fact that the non-manifesting twin was indeed a 
carrier for Fabry disease was confirmed by the 
finding that her son (III. 2) had severe 
a-galactosidase activity deficiency, consistent 
with a hemizygous status. Normal total 
a-galactosidase and a-galactosidase A20 activi­
ties were found in both the mother and father 
of the twins (table 2) as well as in other mem­
bers of this family.16
The heterozygous status of the twins was 
further confirmed by analysing the enzyme 
activities in single hair follicles. As shown in fig 
2, die twin sisters had some hair follicle values 
in die normal range (fig 2 (left) for female con­
trols) but also values distinctly below the 
normal range, that is, in the range of the 
hemizygous son (III.2). These data provide 
further evidence for die heterozygous status of 
the twins. In contrast, none of the 25 hair roots 
analysed in their mother (1.2) showed abnor­
mal (intermediate or deficient) a-galactosidase 
activity (fig 2, right). The enzymatic data 
therefore suggest that Fabry disease in die 
twins occurred as a result of a de novo 
mutation.
a-GALACTOSIDASE A MOLECULAR STUDIES
The seven exons of die a-galactosidase A gene 
of the proband (III. 2) were shown to be ampli-
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Figure 2 a-Galactosidase activity in hair follicles from control female subjects (left panel) and members o f the present 
Fabry family (right panel) .  The activity of (X-galactosidase (a-G AL) was determined as described in the Methods section 
and is expressed as the ratio to (3-hexosaminidase -H EX) activity. Each point corresponds to a different hair root.
fied by PCR and were of the expected size. 
This suggests that if the gene defect of the 
proband is located in the amplified fragments, 
it is too small to be detected by agarose gel 
electrophoresis. We dien determined the nucle­
otide sequence of all the amplified fragments. 
A single alteration was found. At position 
10182 of exon 5 of the a-galactosidase A gene 
(GenBank accession No X I444-8) a G to A 
transition has occurred (fig 3). This alteration 
causes an Asp to Asn amino acid substitution 
at codon 231 of the gene.
The segregation of the G10182A mutation 
was followed in the pedigree by SSCP. Fig 4 
depicts the SSCP analysis of die G10182A 
transition. The proband III.2 showed a mobil­
ity shift for both DNA strands of the exon 5 
PCR product. Botii his mother (II.3) and his 
aunt (II.2) exhibited the normal and abnormal 
patterns, showing heterozygosity for the abnor­
mality. The grandparents (1.1 and L2) had the 
normal pattern.
Since neither maternal grandparent (LI or
1.2) had the mutant allele, and since non­
paternity of the grandfather was unlikely 
because of HLA typing10 and polymorphism
studies (table 1), both the enzymatic and 
molecular findings are consistent with a de 
novo mutation.
ANALYSIS OF THE X INACTIVATION PATTERN
Analysis of the methyl a ti on of the H hal sites 
adjacent to the highly polymorphic CAG 
repeat (90% heterozygosity) o f the human 
androgen receptor gene was informative and 
was performed on cultured skin fibroblasts (fig 
5A) and lymphoid cells (fig 5B) from the twins. 
In this assay, DNA is digested with H hal before 
PCR amplification of die polymorphic repeat. 
Only methylated alleles, present on an inactive 
X  chromosome, can be amplified.26 This semi- 
quantitative method allows reliable
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Figure 3 D N A  sequence gel showing the G 10182A mutation. The G, A , T, and C 
reactions of the proband III. 2 (P) and a normal control (N ) have been loaded alternately. 
The arrows indicate the point mutation.
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Figure 4 Single strand conformation analysis o f exon 5 o f 
the a-galactosidase A  gene. The gel shozos a mobility shift 
for the G10182A transition that results in a D 2 3 I N  amino 
acid substitution. The arrows indicate the shifted bands.
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The analysis was performed on a homogeneous PhastGel 
as described in the Methods section.
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Figure 5 Study of X  inactivation patterns in the present Fabry fam ily by using analysis o f methylation o f H h a l sites at the human androgen receptor 
locus. D N A samples from cultured skin fibroblasts and lymphoid cell lines o f the patients were PCR amplified as described in Methodsj after preincubation 
in the absence (lanes -) or presence (lanes +  )  o f H hal. The androgen receptor alleles in  the twins'fibroblasts (A ) or lymphoid cells (B) are compared to 
those of the lymphoid cells from the rest o f the family. In  fibrobla$is} densitometric analysis o f digested alleles indicated ratios of 0:100 and 97:3 for the 
paternal:maternal alleles in the affected (II. 2) and unaffected (II.3) twin sisters, respectively. In  lymphoid cells (B ) after digestiony ratios of 12:88 and 
37:63 were obtained for the manifesting and unaffected twins3 respectively, Similar results were obtained in five  to 10 separate experiments.
interpretation of the X  inactivation status only 
when perfectly random or almost 100% 
skewed patterns are obtained,26
Fig 5A shows the various alleles in the Fabry 
twins" fibroblasts. PCR without previous H hal 
digestion was also performed on lymphoid cells 
from the parents and the affected child. The 
alleles in the undigested samples were of 
approximately equal intensity. Methylation 
patterns of the twins were determined by com­
paring the intensity of the paternal and mater­
nal alleles in samples that had been digested 
with the restriction endonuclease. A skewed 
methylation pattern in opposite directions was 
apparent in the fibroblast D N A  samples from 
the twins (fig 5A). In one twin (II.2), the ratio 
of paternal:maternal alleles after H hal diges­
tion was 0:100 while this ratio was 97:3 in the 
other twin (II. 3). From this methylation 
pattern, it can be concluded that the paternal 
X  chromosome is preferentially active in the 
Fabry diseased twin and that the maternal X  
chromosome is active in the unaffected sister. 
Since the X  chromosome active in the affected 
twin (II. 2) and the Fabry hemizygote (III.2) is 
of paternal origin, our data also suggest that 
the de novo mutation occurred in the twins5 
father.
In contrast to fibroblast samples, analysis of 
D N A  extracted from lymphoid cell lines of the 
twins did not show opposite inactivation 
patterns, but a slightly preferential inactivation 
of the maternal X  chromosome in both twins 
(fig 5B). These data are in good agreement 
with the a-galactosidase activity levels meas­
ured in the two types of cells (table 2): while a 
clear difference in the activity levels between
the twins was apparent in the fibroblasts, quite 
similar values (slightly below the heterozygote 
range) were observed in lymphoid cell ho- 
mogenates.
D iscussion
This study reports a French family with Fabry 
disease resulting from an as yet undescribed 
mutation. A series of molecular lesions in the 
a-galactosidase A gene causing Fabry disease 
have been reported.12 25 27"*2 Most of these 
mutations are private and include exonic gene 
rearrangements., small deletions and insertions, 
mRNA processing defects, and single base 
substitutions. The single point mutation we 
identified causes a change in the charge of the 
amino acid chain and is therefore very likely to 
affect the a-galactosidase structure or function 
or both. A similar substitution has already been 
described in exon 5 at codon 244.39
The findings of our enzymatic and molecu­
lar studies suggest that in the present family, 
the mutant allele arose in a gamete of the 
grandfather. To our knowledge, this report is 
the third example of Fabry disease resulting 
from a de novo mutation. Indeed, out of the 
many mutations identified in Fabry disease, 
only two instances of de novo mutations have 
been reported, one partial deletion27 and one 
complex mutation in exon 5 .39 Analysis of the 
polymorphism at the human androgen recep­
tor locus indicated that the Fabry mutation 
found in the twins and the hemizygous child 
was carried by the X  chromosome inherited 
from the grandfather, suggesting that the de
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novo mutation in the MZ twins was of paternal 
origin. Whether this defect occurred during 
meiosis or earlier in mitosis of the germ cells 
(causing gonadal mosaicism) remains to be 
elucidated.
Monozygosity of the twins was established 
on the basis of several criteria. In addition to 
the physical similarities and identity of erythro­
cyte and HLA groups, 16 the twin sisters shared 
the same pattern of polymorphic STR markers 
(table 1).
Although monozygotic, the twins exhibited 
discordant expression of Fabry disease. While 
they were both shown to be heterozygous for 
a-galactosidase A deficiency, only one twin 
had clinical signs and symptoms of Fabry 
disease. Two other female twin pairs hetero­
zygous for Fabry disease have previously been  
reported in an English43 44 and a Dutch45 
family. Although their mo no zygosity has not 
been established, these patients also seemed to 
exhibit different expression of the disease.44
The observed phenotypic discordance be­
tween the twins could be explained by X  inac­
tivation dissimilarities. Indeed, uneven lyonisa- 
tion between the twin sisters, that is, a different 
pattern of X  inactivation at the androgen 
receptor locus, was found in skin fibroblasts. 
This type of analysis clearly showed that the 
paternally derived X chromosome was active in 
most skin cells of the Fabry diseased twin while 
the maternally derived X was active in the 
unaffected twin. This X inactivation pattern is 
likely to occur also in the target cells of Fabry 
disease, that is, endothelial and smooth muscle 
cells, 12 since the latter cells and skin fibroblasts 
have the same mesodermal origin.
While completely opposite inactivation pat­
terns were noted in skin fibroblasts of our 
twins, the patterns of méthylation in the 
lymphoid cells were not perfectly random but 
were comparable in both sisters. Several 
hypotheses may account for the discrepancy 
between the two cell types. First, different 
tissues may show different patterns of X inacti­
vation. Second, a selective effect in vitro may 
have resulted in significant clonal outgrowth of 
lymphoblasts in culture, as previously re­
ported.346 Finally, it has been postulated that 
the random inactivation status in lymphocytes 
could result from shared fetal circulation of 
lymphocyte precursors.4 Accordingly, analysis 
of the X inactivation patterns in a cell type 
other than cultured fibroblasts or lymphob­
lasts, for example, peripheral blood leucocytes 
or lymphocytes, was not performed because 
concordant patterns of méthylation in lym­
phocytes (but not in the skin) have previously 
been reported in a twin pair4 and because one 
of our twins is no longer available.
Discordant expression of X  linked disorders 
in monozygotic twin females has been reported 
in at least 22 female twin pairs heterozygous 
for Duchenne muscular dystrophy, deuter- 
anomaly, G6PD deficiency, haemophilia B, 
fragile X  syndrome, and Hunter disease.4"7 Our 
observation adds another twin pair with mark­
edly different X inactivation patterns for an 
hitherto undescribed X linked trait, 
a-galactosidase A deficiency. Thus, as previ­
ously noted,4 9 it appears that concordant 
expression of (at least seven) X linked disor­
ders in MZ female heterozygotes has never 
been reported. This finding has led to the pos­
tulation that MZ twinning events and uneven 
X inactivation are connected.3 4 a 9 47 Indeed, if 
X inactivation occurred independently in each 
female MZ twin, creation of opposite patterns 
of non-random X inactivation would be 
unlikely. Accordingly, it seems that X inactiva­
tion precedes MZ twinning, and that predomi­
nant inactivation of the normal X  in one of the 
twins frequently accompanies the twinning 
process. One possible mechanism for non­
randomness would be the asymmetrical split­
ting of the inner cell mass.10 47
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